UPDATE 1-Alexion Q2 profit beats Street, keeps 2010 view

* Q2 adj EPS $0.39, beats Street by 1 cent

* Revenue rises 36 pct to $125.8 mln

* Keeps fiscal 2010 EPS $1.63 to $1.68, rev $515-$530 mln

July 22 (Reuters) - Alexion Pharmaceuticals Inc (ALXN.O) posted a better-than-expected quarterly profit, helped by higher sales of its drug treating a rare genetic disorder, and reaffirmed its outlook for the full year.

For the second quarter, the company reported a net income of $21.8 million, or 24 cents a share, compared with $16.8 million, or 19 cents a share, a year ago.

Excluding items it earned 39 cents a share. Revenue rose 36 percent to $125.8 million.

Analysts on average expected earnings of 38 cents a share, excluding special items, on revenue of $125.8 million, according to Thomson Reuters I/B/E/S.

Alexion derives all of its revenue from Soliris, which treats paroxysmal nocturnal hemoglobinuria (PNH). The disorder can lead to anemia, fatigue, pain and difficulty in breathing.

The company reiterated its 2010 adjusted earnings forecast of $1.63 to $1.68 a share, on sales of $515 million and $530 million.

Analysts on average were expecting earnings of $1.68 a share, on revenue of $528.8 million.

Shares of the company closed at $51.12 Wednesday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Prem Udayabhanu)